ravulizumab sold brand name ultomiris humanized monoclonal antibody complement inhibitor medication designed treatment paroxysmal nocturnal hemoglobinuria pnh atypical hemolytic uremic syndrome designed bind prevent activation complement component paroxysmal nocturnal hemoglobinuria characterized red blood cell destruction anemia red blood cells unable carry enough oxygen tissues blood clots impaired bone marrow function making enough blood paroxysmal nocturnal hemoglobinuria proteins known complement system part immune system become overactive genetic mutation start attack patients red blood ravulizumab monoclonal antibody type protein designed attach protein part complement attaching protein medicine blocks effect thereby reduces destruction red blood united states ravulizumab indicated treatment adults children one month age older paroxysmal nocturnal hemoglobinuria treatment adults children one month age older atypical hemolytic uremic syndrome ahus inhibit complementmediated thrombotic microangiopathy european union ravulizumab indicated treatment adults paroxysmal nocturnal haemoglobinuria common side effects upper respiratory tract infection nose throat infection nasopharyngitis inflammation nose throat serious side effect meningococcal infection bacterial infection caused neisseria meningitidis cause meningitis ravulizumab developed alexion pharmaceuticals engineered eculizumab longerlasting ravulizumab approved us food drug administration fda december april committee medicinal products human use chmp european medicines agency ema recommended granting conditional marketing authorization ravulizumab approved medical use eu july ravulizumab international nonproprietary name immune activation dostarlimab ibalizumab antineoplastic immunomodulatory drug article stub help wikipedia expanding monoclonal article stub help wikipedia expanding ithttpsenwikipediaorgwikiravulizumab